Systemic sclerosis & Raynaud's
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial
Authors' conclusion
AMC may be a biomarker of disease progression in SSc-ILD, especially in those with early SSc with elevated circulating inflammatory markers.
Study context
- Population
- Adults with dcSSc for ≤ 60 months and SSc-ILD enrolled in the phase 3 focuSSced trialSSc-ILD
- Participants
- 136 adults
- Comparison
- Association of baseline absolute monocyte count with change in forced vital capacity (FVC) at week 48, by treatment group (tocilizumab vs placebo)
- Primary endpoint
- Association of baseline absolute monocyte count (AMC) with change in FVC from baseline
- Follow-up
- Week 48
Methodological detailspost hoc analysis, multicentre, double-blind, placebo-controlled, General Linear Model adjusted for potential confounders
- Post hoc analysis
- Multicentre
- Double-blind
- Placebo-controlled
- General Linear Model adjusted for potential confounders
Primary result
As reported in the abstract
Association of baseline AMC with change in FVC from baseline at week 48
Placebo: inverse association, unadjusted model, β coefficient
−0.539
95% CI −1.032 to −0.047p-value=0.032
Placebo: inverse association, multivariable-adjusted model, β coefficient
−0.573
95% CI −1.086 to −0.060p-value=0.029
Original publication
Baseline absolute monocyte count predicts lung function decline among patients with systemic sclerosis-associated interstitial lung disease: A post hoc analysis from the focuSSced trial. Semin Arthritis Rheum. Published 14 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →